NCT01218100
Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
See it on ClinicalTrials.gov ↗661 people
42.1%
57.9%
278 womenmiddle line = equal numbers383 men
- Phase
- PHASE4
- Paid for by
- Forest Laboratories
- Finished
- 2011-06
- Health conditions
- Stage 2 Diastolic Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 64 Years
- Average age
- mean 49.2 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 64 Years.”
- No pregnant women
Women who were pregnant could not join.
“Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen”
Study titles and rules are shown in their original English.